Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.
Payen T, Trédaniel J, Moreau L, Larivé S, Le Treut J, Nocent C, Hominal S, Grangeon V, Bizec JL, Molinier O, Debieuvre D. Payen T, et al. Among authors: nocent c. Respir Med Res. 2021 Nov;80:100795. doi: 10.1016/j.resmer.2020.100795. Epub 2020 Nov 1. Respir Med Res. 2021. PMID: 34242973
Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A). Short version.
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, Didier A. Raherison-Semjen C, et al. Among authors: nocent c. Respir Med Res. 2022 May;81:100898. doi: 10.1016/j.resmer.2022.100898. Epub 2022 May 5. Respir Med Res. 2022. PMID: 35526320
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
[Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version].
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, Didier A. Raherison-Semjen C, et al. Among authors: nocent c. Rev Mal Respir. 2021 Dec;38(10):1048-1083. doi: 10.1016/j.rmr.2021.08.002. Epub 2021 Nov 17. Rev Mal Respir. 2021. PMID: 34799211 French. No abstract available.
[Erratum to "Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version" [Rev. Mal. Respir. 38 (2021) 1048-1083]].
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, Didier A. Raherison-Semjen C, et al. Among authors: nocent c. Rev Mal Respir. 2022 Feb;39(2):188-189. doi: 10.1016/j.rmr.2022.01.001. Epub 2022 Jan 25. Rev Mal Respir. 2022. PMID: 35090791 French. No abstract available.
[Erratum to "Updated guidelines for management of asthmatic patients (from 12 years and older). Short version" [Rev. Mal. Respir. 38 (2021) e1-e13]].
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, Didier A. Raherison-Semjen C, et al. Among authors: nocent c. Rev Mal Respir. 2022 Feb;39(2):e33-e34. doi: 10.1016/j.rmr.2022.01.002. Epub 2022 Jan 25. Rev Mal Respir. 2022. PMID: 35090792 French. No abstract available.
[Patients in the IDEAL cohort: A snapshot of severe asthma in France].
Taillé C, Pison C, Nocent C, Devouassoux G, Prud'homme A, Gruber A, Gunsoy N, Albers F. Taillé C, et al. Among authors: nocent c. Rev Mal Respir. 2019 Feb;36(2):179-190. doi: 10.1016/j.rmr.2018.10.005. Epub 2018 Nov 11. Rev Mal Respir. 2019. PMID: 30429093 French.
[Features of asthma in women: what is the relationship with hormonal status?].
Taillé C, Raherison C, Sobaszek A, Thumerelle C, Prudhomme A, Biron E, Nocent C, Tillie-Leblond I. Taillé C, et al. Among authors: nocent c. Rev Mal Respir. 2014 Jun;31(6):469-77. doi: 10.1016/j.rmr.2014.02.005. Epub 2014 Mar 24. Rev Mal Respir. 2014. PMID: 25012033 Review. French.
[Updated guidelines for management of asthmatic patients (from 12 years and older). Short version].
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, Didier A. Raherison-Semjen C, et al. Among authors: nocent c. Rev Mal Respir. 2021 Dec;38(10):e1-e13. doi: 10.1016/j.rmr.2021.08.004. Epub 2021 Nov 26. Rev Mal Respir. 2021. PMID: 34840037 French. No abstract available.
Lung function parameters in omalizumab responder patients: An interesting tool?
Paganin F, Mangiapan G, Proust A, Prudhomme A, Attia J, Marchand-Adam S, Pellet F, Milhe F, Melloni B, Bernady A, Raspaud C, Nocent C, Berger P, Guilleminault L. Paganin F, et al. Among authors: nocent c. Allergy. 2017 Dec;72(12):1953-1961. doi: 10.1111/all.13202. Epub 2017 Jun 14. Allergy. 2017. PMID: 28517027
15 results